Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
June 23, 2011/PRNewswire/ --
Jubilant Biosys Ltd.,
Bengaluru, based subsidiary of Jubilant Life Sciences Ltd., and
AstraZeneca, today announced another successful delivery of an
early stage milestone in the Pain therapeutic area.
initiated two years ago in the Neuroscience therapeutic area, has
now expanded to Cardiovascular and Metabolic diseases and focuses
on the delivery of a steady stream of preclinical outcomes to
AstraZeneca, by Jubilant. AstraZeneca owns the compounds developed
under the collaboration with worldwide development and
commercialization rights. Jubilant derives research funding and
success-based development and commercialization milestones.
Commenting on this
development,Sri Mosur, CEO & President, Global Drug Discovery
& Development, Jubilant said: "We are pleased that we have
delivered outcomes and early success to the portfolio efforts at
AstraZeneca. This is the result of excellent collaboration between
scientists at Jubilant and AstraZeneca.
"Partnering is a
strategic priority for AstraZeneca at all stages of drug discovery
and development," says Christof Angst, CNS & Pain Innovative
Medicines, Vice-President, Strategy and Externalisation. "By
combining our strengths with those of our partners, we are in a
better position to deliver new medicines that can make a meaningful
difference to patients' lives."
Jubilant Biosys Ltd.
is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd,
headquartered in Noida, India. Jubilant Biosys, provides integrated
drug discovery and development solutions to the global
pharmaceutical industry. It is a pioneer in collaborative discovery
research and development and is engaged in multiple partnerships
with global pharmaceutical industry in therapeutic areas of
Oncology, CNS and CVMED.
AstraZeneca is a
global, innovation-driven biopharmaceutical business with a primary
focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular,
neuroscience, respiratory and inflammation, oncology and infectious
disease. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients
Contact For Business
email@example.com , +91-9611104886
Source: Jubilant Biosys Ltd.
Posted: June 2011